This week, five biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

La Jolla Pharmaceutical Company (LJPC) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, LJPC also gets A’s. For more information, get Portfolio Grader’s complete analysis of LJPC stock.

This week, Incyte Corporation (INCY) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. For more information, get Portfolio Grader’s complete analysis of INCY stock.

Ambit Biosciences Corp. (AMBI) is seeing ratings go up from a C last week to a B this week. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

This week, Progenics Pharmaceuticals, Inc. (PGNX) pushes up from a C to a B rating. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

Celladon Corporation (CLDN) shows solid improvement this week. The company’s rating rises from a B to an A. For more information, get Portfolio Grader’s complete analysis of CLDN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.